The US presidential election slowed the flow of venture capital funding announcements during the first week of November, but the flood of new biopharmaceutical VC deals resumed during the second week of the month with several $100m-plus mega-rounds, bringing the total for the past two weeks to $1.2bn and counting.
Investors continue to reveal new funds for health care and life science opportunities as well with $1.3bn in freshly raised capital across three funds. One of these was Fountain Healthcare Partners’ third fund, which totaled €125m ($148.6m) – an amount that exceeded an initial €100m goal and increased from a previously announced first close of €118m
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
